$LGND
LIGAND PHARMACEUTICALS INC

2017 Q2 Form 10-Q Financial Statement

#000088616317000091 Filed on August 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $28.00M $19.52M
YoY Change 43.41% 5.99%
Cost Of Revenue $903.0K $720.0K
YoY Change 25.42% -72.31%
Gross Profit $27.09M $18.80M
YoY Change 44.1% 18.86%
Gross Profit Margin 96.77% 96.31%
Selling, General & Admin $6.550M $6.860M
YoY Change -4.52% -5.12%
% of Gross Profit 24.18% 36.49%
Research & Development $4.822M $4.914M
YoY Change -1.87% 43.85%
% of Gross Profit 17.8% 26.14%
Depreciation & Amortization $2.600M $100.0K
YoY Change 2500.0% -84.25%
% of Gross Profit 9.6% 0.53%
Operating Expenses $4.822M $4.914M
YoY Change -1.87% 43.85%
Operating Profit $13.02M $3.969M
YoY Change 227.92% -9.07%
Interest Expense $3.341M $3.051M
YoY Change 9.51% 2.76%
% of Operating Profit 25.67% 76.87%
Other Income/Expense, Net -$4.715M -$14.02M
YoY Change -66.37% -178.21%
Pretax Income $8.300M -$10.05M
YoY Change -182.58% -145.09%
Income Tax $22.42M -$3.881M
% Of Pretax Income 270.11%
Net Earnings $73.16M -$6.170M
YoY Change -1285.74% -126.18%
Net Earnings / Revenue 261.33% -31.61%
Basic Earnings Per Share $3.45 -$0.30
Diluted Earnings Per Share $2.99 -$0.30
COMMON SHARES
Basic Shares Outstanding 21.21M shares 20.83M shares
Diluted Shares Outstanding 24.44M shares 20.83M shares

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $172.6M $107.0M
YoY Change 61.31% -41.08%
Cash & Equivalents $60.22M $61.35M
Short-Term Investments $112.4M $45.60M
Other Short-Term Assets $1.072M $2.602M
YoY Change -58.8% 44.48%
Inventory $6.809M $3.835M
Prepaid Expenses $2.122M
Receivables $13.50M $10.00M
Other Receivables $3.200M $3.700M
Total Short-Term Assets $197.2M $126.6M
YoY Change 55.79% -35.67%
LONG-TERM ASSETS
Property, Plant & Equipment $1.875M $1.181M
YoY Change 58.76% 191.6%
Goodwill $72.21M $72.36M
YoY Change -0.21% 491.27%
Intangibles $199.3M $210.1M
YoY Change -5.17% 324.23%
Long-Term Investments $6.014M $18.73M
YoY Change -67.9% -44.9%
Other Assets $1.668M $603.0K
YoY Change 176.62% 100.33%
Total Long-Term Assets $442.8M $490.2M
YoY Change -9.67% 353.77%
TOTAL ASSETS
Total Short-Term Assets $197.2M $126.6M
Total Long-Term Assets $442.8M $490.2M
Total Assets $640.0M $616.8M
YoY Change 3.77% 102.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.799M $2.336M
YoY Change -22.99% -13.74%
Accrued Expenses $5.325M $4.951M
YoY Change 7.55% -12.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $218.6M $207.6M
YoY Change 5.3% 12875.0%
Total Short-Term Liabilities $225.8M $220.3M
YoY Change 2.49% 1127.63%
LONG-TERM LIABILITIES
Long-Term Debt $24.30M $34.70M
YoY Change -29.97% -82.72%
Other Long-Term Liabilities $915.0K $398.0K
YoY Change 129.9% -45.78%
Total Long-Term Liabilities $915.0K $398.0K
YoY Change 129.9% -45.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $225.8M $220.3M
Total Long-Term Liabilities $915.0K $398.0K
Total Liabilities $230.6M $224.9M
YoY Change 2.55% -4.59%
SHAREHOLDERS EQUITY
Retained Earnings -$402.3M -$401.2M
YoY Change 0.29% -36.82%
Common Stock $21.00K $21.00K
YoY Change 0.0% 5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $385.1M $391.9M
YoY Change
Total Liabilities & Shareholders Equity $640.0M $616.8M
YoY Change 3.77% 102.39%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income $73.16M -$6.170M
YoY Change -1285.74% -126.18%
Depreciation, Depletion And Amortization $2.600M $100.0K
YoY Change 2500.0% -84.25%
Cash From Operating Activities $15.40M $10.40M
YoY Change 48.08% 4.0%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$18.50M
YoY Change -99.46% 351.22%
Acquisitions
YoY Change
Other Investing Activities $34.30M $36.70M
YoY Change -6.54% -153.81%
Cash From Investing Activities $34.20M $18.30M
YoY Change 86.89% -125.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.500M
YoY Change -100.0% -67.39%
NET CHANGE
Cash From Operating Activities 15.40M 10.40M
Cash From Investing Activities 34.20M 18.30M
Cash From Financing Activities 0.000 1.500M
Net Change In Cash 49.60M 30.20M
YoY Change 64.24% -152.43%
FREE CASH FLOW
Cash From Operating Activities $15.40M $10.40M
Capital Expenditures -$100.0K -$18.50M
Free Cash Flow $15.50M $28.90M
YoY Change -46.37% 104.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000886163
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21053494 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
LIGAND PHARMACEUTICALS INC
CY2016Q2 lgnd Collaborative Research And Development And Other Revenues
CollaborativeResearchAndDevelopmentAndOtherRevenues
5881000 USD
lgnd Collaborative Research And Development And Other Revenues
CollaborativeResearchAndDevelopmentAndOtherRevenues
15798000 USD
CY2017Q2 lgnd Collaborative Research And Development And Other Revenues
CollaborativeResearchAndDevelopmentAndOtherRevenues
8234000 USD
lgnd Collaborative Research And Development And Other Revenues
CollaborativeResearchAndDevelopmentAndOtherRevenues
12151000 USD
CY2016Q4 lgnd Commercial License Rights
CommercialLicenseRights
25821000 USD
CY2017Q2 lgnd Commercial License Rights
CommercialLicenseRights
22962000 USD
CY2016Q4 lgnd Current Portion Of Liability For Contingent Value Rights
CurrentPortionOfLiabilityForContingentValueRights
5088000 USD
CY2017Q2 lgnd Current Portion Of Liability For Contingent Value Rights
CurrentPortionOfLiabilityForContingentValueRights
86000 USD
lgnd Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
900000 USD
lgnd Equity Receivedin Repaymentof Note Receivable
EquityReceivedinRepaymentofNoteReceivable
1200000 USD
lgnd Equity Receivedin Repaymentof Note Receivable
EquityReceivedinRepaymentofNoteReceivable
0 USD
lgnd Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant
IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant
310000 USD
lgnd Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant
IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant
-77000 USD
CY2016Q4 lgnd Liability For Contingent Value Rights
LiabilityForContingentValueRights
2916000 USD
CY2017Q2 lgnd Liability For Contingent Value Rights
LiabilityForContingentValueRights
3860000 USD
lgnd Non Cash Change In Estimated Fair Value Of Contingent Value Rights
NonCashChangeInEstimatedFairValueOfContingentValueRights
-1638000 USD
lgnd Non Cash Change In Estimated Fair Value Of Contingent Value Rights
NonCashChangeInEstimatedFairValueOfContingentValueRights
-966000 USD
CY2017Q2 lgnd Note Receivable Interestand Principal Reductionper Dollarof Value
NoteReceivableInterestandPrincipalReductionperDollarofValue
0.50
lgnd Payments To Contingent Value Right Holders
PaymentsToContingentValueRightHolders
5635000 USD
lgnd Payments To Contingent Value Right Holders
PaymentsToContingentValueRightHolders
4998000 USD
lgnd Proceedsfrom Repaymentof Commercial License Rights
ProceedsfromRepaymentofCommercialLicenseRights
0 USD
lgnd Proceedsfrom Repaymentof Commercial License Rights
ProceedsfromRepaymentofCommercialLicenseRights
2859000 USD
lgnd Purchasefor Commercial License Rights
PurchaseforCommercialLicenseRights
17691000 USD
lgnd Purchasefor Commercial License Rights
PurchaseforCommercialLicenseRights
0 USD
CY2017Q2 lgnd Working Capital Deficit
WorkingCapitalDeficit
28700000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2734000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1980000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1244000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-187000 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1799000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-331000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
44000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6397000 USD
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5325000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
829000 USD
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
448000 USD
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
942000 USD
CY2017Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
908000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2743000 USD
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3059000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3761440 shares
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
769653000 USD
CY2017Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
784376000 USD
CY2016Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
4647000 USD
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
8766000 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
4624000 USD
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
10669000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5378000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5720000 USD
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3811813 shares
CY2016Q4 us-gaap Assets
Assets
601585000 USD
CY2017Q2 us-gaap Assets
Assets
640024000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
163053000 USD
CY2017Q2 us-gaap Assets Current
AssetsCurrent
197177000 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122296000 USD
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
112404000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1564000 USD
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2065000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000 USD
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
44000 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
120758000 USD
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
110383000 USD
CY2016Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
-332000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
-1638000 USD
CY2017Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
-825000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
-966000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97428000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61350000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18752000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60223000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-36078000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41471000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
33333333 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
33333333 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20909301 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21049741 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20909301 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21049741 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5995000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-721000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6012000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11453000 USD
CY2016Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
212910000 USD
CY2017Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
218630000 USD
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
720000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1675000 USD
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
903000 USD
CY2016Q2 us-gaap Cost Of Services Amortization
CostOfServicesAmortization
2681000 USD
us-gaap Cost Of Services Amortization
CostOfServicesAmortization
5206000 USD
CY2017Q2 us-gaap Cost Of Services Amortization
CostOfServicesAmortization
2706000 USD
us-gaap Cost Of Services Amortization
CostOfServicesAmortization
5420000 USD
CY2016Q4 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
29563000 USD
CY2017Q2 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
24293000 USD
CY2016 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days
DebtInstrumentConvertibleThresholdConsecutiveTradingDays
P50D
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
123891000 USD
CY2017Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
138837000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5388000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5564000 USD
CY2016Q2 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0 USD
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
1139000 USD
CY2017Q2 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0 USD
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0 USD
CY2016Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
0 USD
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
731000 USD
CY2017Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
0 USD
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
0 USD
CY2016Q2 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
0 USD
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
408000 USD
CY2017Q2 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
0 USD
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
0 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.53
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2017Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.27
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.23
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2603000 USD
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1878000 USD
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
8345000 USD
CY2017Q2 us-gaap Equity Method Investments
EquityMethodInvestments
6014000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7237000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.04
CY2017Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14309000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6549000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13872000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
72207000 USD
CY2017Q2 us-gaap Goodwill
Goodwill
72207000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10051000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-480000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8300000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
14493000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6170000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-293000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
6058000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
11137000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.30
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.29
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.53
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.30
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2017Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.26
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.48
CY2016Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.04
CY2017Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2016Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2016Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-11138000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-12743000 USD
CY2017Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1248000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2330000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3881000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2242000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3356000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
36000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
132000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3323000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2153000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3791000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1263000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-187000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3224000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2202000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4286000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
629000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-314000 USD
CY2016Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2017Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1079702 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1010505 shares
CY2016Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2017Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
967533 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
961021 shares
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
204705000 USD
CY2017Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
199284000 USD
CY2016Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
276912000 USD
CY2017Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
271491000 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
3051000 USD
us-gaap Interest Expense
InterestExpense
6055000 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
2860000 USD
us-gaap Interest Expense
InterestExpense
5803000 USD
us-gaap Interest Paid
InterestPaid
919000 USD
us-gaap Interest Paid
InterestPaid
919000 USD
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
899000 USD
CY2017Q2 us-gaap Interest Payable Current
InterestPayableCurrent
853000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
1923000 USD
CY2017Q2 us-gaap Inventory Net
InventoryNet
6809000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
230732000 USD
CY2017Q2 us-gaap Liabilities
Liabilities
230615000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
601585000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
640024000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
225840000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227129000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1672000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-61543000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8535000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23485000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34608000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6170000 USD
us-gaap Net Income Loss
NetIncomeLoss
438000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
6058000 USD
us-gaap Net Income Loss
NetIncomeLoss
11137000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14020000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19544000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4715000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8740000 USD
CY2016Q4 us-gaap Notes And Loans Receivable Gross Current
NotesAndLoansReceivableGrossCurrent
3207000 USD
CY2017Q2 us-gaap Notes And Loans Receivable Gross Current
NotesAndLoansReceivableGrossCurrent
3207000 USD
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15552000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30105000 USD
CY2017Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14980000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
34031000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3969000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
19064000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
13015000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
23233000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1124000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1238000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2175000 USD
CY2017Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1072000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1744000 USD
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1668000 USD
CY2016Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
539000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-559000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
90000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
24000 USD
CY2016Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
364000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
600000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
136000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-292000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
687000 USD
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
915000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
501000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
892000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
218000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
359000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
204000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
75000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
502000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4042000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
51887000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
22077000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
83523000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
92504000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
700000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1021000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
199000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
49892000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
124282000 USD
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
300000 USD
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
83268000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2482000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2370000 USD
us-gaap Profit Loss
ProfitLoss
438000 USD
us-gaap Profit Loss
ProfitLoss
11137000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1819000 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1875000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
602000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
248000 USD
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
14700000 USD
CY2017Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
13462000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4914000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8915000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4822000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13495000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-431127000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-402340000 USD
CY2016Q2 us-gaap Revenues
Revenues
19521000 USD
us-gaap Revenues
Revenues
49169000 USD
CY2017Q2 us-gaap Revenues
Revenues
27995000 USD
us-gaap Revenues
Revenues
57264000 USD
CY2016Q2 us-gaap Royalty Revenue
RoyaltyRevenue
9754000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
24144000 USD
CY2017Q2 us-gaap Royalty Revenue
RoyaltyRevenue
14211000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
38441000 USD
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3886000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9227000 USD
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5550000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6672000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8766000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10669000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.50
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.47
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1400000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
35.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
198101 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1754275 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1871504 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.12
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
29.11
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
101.93
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7M6D
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y9M18D
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
122296000 USD
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
112404000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80872 shares
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
-77615000 USD
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
0 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
341290000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
385116000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1198000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
24000 USD
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20831809 shares
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20832000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20765053 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20765000 shares
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23216000 shares
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23215900 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23117164 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23117000 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20831809 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20765053 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21012611 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20974738 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20832000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20765000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21013000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20975000 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
156054 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
170900 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0000886163-17-000091-index-headers.html Edgar Link pending
0000886163-17-000091-index.html Edgar Link pending
0000886163-17-000091.txt Edgar Link pending
0000886163-17-000091-xbrl.zip Edgar Link pending
ex101lgndaziyoroyaltyagr.htm Edgar Link pending
ex101lgndaziyoroyaltyagr001.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr002.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr003.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr004.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr005.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr006.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr007.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr008.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr009.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr010.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr011.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr012.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr013.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr014.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr015.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr016.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr017.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr018.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr019.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr020.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr021.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr022.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr023.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr024.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr025.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr026.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr027.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr028.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr029.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr030.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr031.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr032.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr033.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr034.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr035.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr036.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr037.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr038.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr039.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr040.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr041.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr042.jpg Edgar Link pending
ex101lgndaziyoroyaltyagr043.jpg Edgar Link pending
ex102lgndcormatrixarinte.htm Edgar Link pending
ex102lgndcormatrixarinte001.jpg Edgar Link pending
ex102lgndcormatrixarinte002.jpg Edgar Link pending
ex102lgndcormatrixarinte003.jpg Edgar Link pending
ex102lgndcormatrixarinte004.jpg Edgar Link pending
ex102lgndcormatrixarinte005.jpg Edgar Link pending
ex102lgndcormatrixarinte006.jpg Edgar Link pending
ex102lgndcormatrixarinte007.jpg Edgar Link pending
ex102lgndcormatrixarinte008.jpg Edgar Link pending
ex102lgndcormatrixarinte009.jpg Edgar Link pending
ex102lgndcormatrixarinte010.jpg Edgar Link pending
ex102lgndcormatrixarinte011.jpg Edgar Link pending
ex102lgndcormatrixarinte012.jpg Edgar Link pending
ex102lgndcormatrixarinte013.jpg Edgar Link pending
ex102lgndcormatrixarinte014.jpg Edgar Link pending
ex102lgndcormatrixarinte015.jpg Edgar Link pending
ex102lgndcormatrixarinte016.jpg Edgar Link pending
ex102lgndcormatrixarinte017.jpg Edgar Link pending
ex102lgndcormatrixarinte018.jpg Edgar Link pending
ex102lgndcormatrixarinte019.jpg Edgar Link pending
ex102lgndcormatrixarinte020.jpg Edgar Link pending
ex102lgndcormatrixarinte021.jpg Edgar Link pending
ex102lgndcormatrixarinte022.jpg Edgar Link pending
ex102lgndcormatrixarinte023.jpg Edgar Link pending
ex102lgndcormatrixarinte024.jpg Edgar Link pending
ex102lgndcormatrixarinte025.jpg Edgar Link pending
ex102lgndcormatrixarinte026.jpg Edgar Link pending
ex102lgndcormatrixarinte027.jpg Edgar Link pending
ex102lgndcormatrixarinte028.jpg Edgar Link pending
ex102lgndcormatrixarinte029.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lgnd-20170630.xml Edgar Link completed
lgnd-20170630.xsd Edgar Link pending
lgnd-20170630_cal.xml Edgar Link unprocessable
lgnd-20170630_def.xml Edgar Link unprocessable
lgnd-20170630_lab.xml Edgar Link unprocessable
lgnd-20170630_pre.xml Edgar Link unprocessable
lgnd-6301710q.htm Edgar Link pending
lgnd_63017exhibit311.htm Edgar Link pending
lgnd_63017exhibit312.htm Edgar Link pending
lgnd_63017exhibit321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending